Add Formweb to your mobile device
Following is a P and T Committee update (from the November 17th meeting). Starting date for specific programs is 23 Nov 2015, unless otherwise noted. Please let me know if you have any questions or comments. Don’t forget to check the “New Drug Monitoring Spotlight” section of the website, which provides important monitoring information about newly approved drugs. Also, attached is the updated version of the “Not Stocked, Not Ordered” drug list with the new additions highlighted in red.
Below is the memo with links to the drug monographs, protocols, and formulary documents. Click to access the full P&T packet for this month, or here to access the P&T packet archive.
|
Drug or Drug Class |
Formulary Decision |
Comments |
| daclatasvir (Daklinza) | Non-formulary, not stocked. |
Patient to use own supply. Initiation deferred to outpatient setting. |
| Non-formulary, not stocked. |
Supplied by specialty pharmacy directly to patient. Patient to use own drug supply if needed. Defer initiation to outpatient therapy. |
|
| pirfenidone (Esbriet) | Non-formulary, not stocked. |
Supplied by specialty pharmacy directly to patient. Patient to use own supply if needed. Defer initiation to outpatient therapy. |
| nintedanib (Ofev) | Non-formulary, not stocked. |
Supplied by specialty pharmacy directly to patient. Patient to use own supply if needed. Defer initiation to outpatient therapy. |
| dinutuximab (Unituxin) | Non-formulary, not stocked. | If required, patient will be transferred to St. Jude facility in Memphis, TN. |
| methylphenidate extended-release (Aptensio XR) |
Non-formulary, not stocked. Therapeutic Interchange Approved. |
Interchange to generic extended-release methylphenidate products at an equivalent dose. |
| desoximetasone (Topicort Spray) |
Non-formulary, not stocked Therapeutic Interchange Approved |
Interchange to fluocinonide topical solution 0.05% |
|
Non-formulary, not stocked Therapeutic Interchange Approved |
Empagliflozin and metFORMIN will the dispensed separately. | |
| idarucizumab (Praxbind) | Formulary, restrictions to be announced |
Protocol & criteria for use to be developed. Currently no restrictions. |
| dantrolene inj. (Ryanodex) | Formulary | For use in malignant hyperthermia emergencies. |
| Enteral Feedings | Management of enteral feedings was approved for transition to Clinical Dietitians by Jan 2016. | Clinical Dietitians will participate in NSS training program prior to initiation |
| Malignant Hyperthermia Awareness Program | Protocol and Guidelines | Updates to policy, procedures and ordersets currently underway. |
| prochlorperazine Injection Shortage | Automatic Interchange Approved/Re-instated |
prochlorperazine IV will be converted to ondansetron IV. prochlorperazine IM will be converted to trimethoBENZamide. |
| Carbapenem and pipercillin/tazobactam shortages |
Antipseudomonal carbapenem shortage continues. Interchange between 3 products approved. Remains restricted to ID. Pip/Taz 4.5 g shortage possible. |
Carbapenem interchange will be based on product availability: meropenem, imipenem/cilastatin, & doripenem. Pip/Taz 4.5 g dose currently in stock. If shortage occurs, additional information will be provided. |